3 completed, 2 active not recruiting, 1 recruiting. 3 Phase 2, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Aggressive Fibromatosis: new trials by email Literature Review of Aggressive Fibromatosis trials Research Report on Aggressive Fibromatosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Nirogacestat - Desmoid Tumor, Aggressive Fibromatosis | Phase 4 | Recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 50 | 2025-09-17 | 2026-10-13 |
| A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) Nirogacestat oral tablet - Desmoid Tumor, Aggressive Fibromatosis | Phase 2 | Active not recruiting | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 20 | 2025-08-08 | 2026-09-15 |
| Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Nirogacestat oral tablet, Placebo Oral Tablet - Desmoid Tumor, Aggressive Fibromatosis | Phase 3 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 142 | 2019-04-17 | 2026-08-20 |
| National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES) biopsy, biobank constitution, Coloscopy - Aggressive Fibromatosis | Not applicable | Active not recruiting | Centre Oscar Lambret | 628 | 2016-03-22 | 2026-03-30 |
| Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis PF-03084014 - Desmoid Tumors, Aggressive Fibromatosis | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2013-10-31 | 2024-02-06 |
| Study to Evaluate Imatinib in Desmoid Tumors Imatinib - Aggressive Fibromatosis, Desmoid Tumor | Phase 2 | Completed | Heidelberg University | 39 | 2010-06-01 | 2017-05-03 |
Desmoid Tumors (6)
Fibroma (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Connective Tissue (6) · Neoplasms, Connective and Soft Tissue (6) · Neoplasms, Fibrous Tissue (6)
nirogacestat (4) · Biopsy (1) · Blood Specimen Collection (1) · Imatinib Mesylate (1)
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (3) · Centre Oscar Lambret (1) · Heidelberg University (1) · National Cancer Institute (NCI) (1)
Germany (3) · Belgium (2) · Italy (2) · Netherlands (2) · United Kingdom (2) · United States (2) · Canada (1) · France (1) · Japan (1) · Spain (1)
Bernd Kasper, MD (1) · Bernd Kasper, PD Dr. med. (1) · Geraldine H O'Sullivan Coyne, M.D. (1)
PMID 26861905, PMID 28282612, PMID 28350521, PMID 35294527, PMID 36884323, PMID 37347393, PMID 41115259